Anhydrous Tacrolimus
Tacrolimus may increase the immunosuppressive activities of Ustekinumab.
Anthrax immune globulin, human
The risk or severity of adverse effects can be increased when Ustekinumab is combined with Anthrax immune globulin human.
BCG Vaccine
The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Ustekinumab.
Advertisement
BCG, Live, Connaught Strain
The risk or severity of adverse effects can be increased when Ustekinumab is combined with Bacillus calmette-guerin substrain connaught live antigen.
BCG, Live, Tice Strain
The risk or severity of adverse effects can be increased when Ustekinumab is combined with Bacillus calmette-guerin substrain tice live antigen.
Belimumab
The risk or severity of adverse effects can be increased when Ustekinumab is combined with Belimumab.
Advertisement
Denosumab
The risk or severity of adverse effects can be increased when Denosumab is combined with Ustekinumab.
Fingolimod
Ustekinumab may increase the immunosuppressive activities of Fingolimod.
Hepatitis A Vaccine, Inactivated
The risk or severity of adverse effects can be increased when Ustekinumab is combined with Hepatitis A Vaccine.
Advertisement
Hepatitis B Surface Antigen Vaccine
The risk or severity of adverse effects can be increased when Ustekinumab is combined with Hepatitis B Vaccine (Recombinant).
Infliximab
Ustekinumab may increase the immunosuppressive activities of Infliximab.
Infliximab-Abda
Ustekinumab may increase the immunosuppressive activities of Infliximab.
Infliximab-Dyyb
Ustekinumab may increase the immunosuppressive activities of Infliximab.
Leflunomide
The risk or severity of adverse effects can be increased when Ustekinumab is combined with Leflunomide.
Natalizumab
The risk or severity of adverse effects can be increased when Ustekinumab is combined with Natalizumab.
Ocrelizumab
Ocrelizumab may increase the immunosuppressive activities of Ustekinumab.
Pimecrolimus
The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Ustekinumab.
Rabies Immune Globulin, Human
The risk or severity of adverse effects can be increased when Ustekinumab is combined with Human rabies virus immune globulin.
Rabies Virus Vaccine Flury-Lep Strain
The risk or severity of adverse effects can be increased when Ustekinumab is combined with Rabies virus inactivated antigen, A.
Roflumilast
Roflumilast may increase the immunosuppressive activities of Ustekinumab.
ROTAVIRUS VACCINE, LIVE
The risk or severity of adverse effects can be increased when Ustekinumab is combined with Rotavirus Vaccine.
Rubella Virus Vaccine Live (wistar Ra 27-3 Strain)
The risk or severity of adverse effects can be increased when Ustekinumab is combined with Rubella virus vaccine.
Salmonella enterica subsp. enterica serovar typhi
The risk or severity of adverse effects can be increased when Ustekinumab is combined with Salmonella typhi ty21a live antigen.
sipuleucel-T
The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Ustekinumab.
Tacrolimus
Tacrolimus may increase the immunosuppressive activities of Ustekinumab.
Tetanus Toxoid Vaccine, Inactivated
The risk or severity of adverse effects can be increased when Ustekinumab is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).
Tofacitinib
Ustekinumab may increase the immunosuppressive activities of Tofacitinib.
Trastuzumab
Trastuzumab may increase the neutropenic activities of Ustekinumab.
Typhoid Vaccine Live Ty21a
The risk or severity of adverse effects can be increased when Ustekinumab is combined with Salmonella typhi ty21a live antigen.
Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain
The risk or severity of adverse effects can be increased when Ustekinumab is combined with Salmonella typhi ty2 vi polysaccharide antigen.
Varicella Virus Vaccine Live (Oka-Merck) strain
The risk or severity of adverse effects can be increased when Ustekinumab is combined with Varicella Zoster Vaccine (Live/Attenuated).
Yellow Fever Vaccine
The risk or severity of adverse effects can be increased when Ustekinumab is combined with Yellow Fever Vaccine.
Yellow-Fever Virus Vaccine, 17D-204 strain
The risk or severity of adverse effects can be increased when Ustekinumab is combined with Yellow Fever Vaccine.
